Functionalized stilbene derivatives as improved vascular targeting agents
US7384925B2 · kind B2 · utility
1Cited by
8References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 18, 2005 |
| Grant date | Jun 10, 2008 |
| Priority date | — |
| Expiry date | Nov 2, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.